Senthilnath (Senthil) Lakshmanachetty, PhD
My scientific interest is in Cancer Immunotherapy. Previously, as a Postdoctoral Fellow, under the guidance of Drs. Siddhartha Mitra and Sujatha Venkataraman at University of Colorado Anschutz medical campus, I worked on combining macrophage-mediated immunotherapy and radiation therapy to effectively treat H3K27M-mutated Diffuse Midline Glioma. Currently, in the Okada lab, I am interested in the development of SynNotch and “Off-the-shelf” CAR-T cell products for the treatment of patients with Diffuse Intrinsic Pontine Glioma and Glioblastoma.
Interests outside the lab: Traveling, hiking, watching basketball, and reading.
Email: Senthilnath.lakshmanachetty@ucsf.edu
2008, B.Tech. in Biotechnology, Sathyabama University, India
2012, M.S. in Biotechnology, University of Texas at San Antonio
2018, Ph.D. in Cell biology, Stem cells, and Development, University of Colorado Anschutz Medical Campus
2019-2022, Postdoctoral Fellow, University of Colorado Anschutz Medical Campus
2020 Cancer League of Colorado Pilot Award
2012 International student grant, University of Texas at San Antonio
Mapping the tumor-infiltrating immune cells during glioblastoma progression.
Lakshmanachetty S, Mitra SS.
Nat Immunol. 2022 Jun; 23(6):826-828. PMID: 35624212.
Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
Madhavan K*, Balakrishnan I*, Lakshmanachetty S*, Pierce A, Sanford B, Fosmire S, Elajaili HB, Walker F, Wang D, Nozik ES, Mitra SS, Dahl NA, Vibhakar R, Venkataraman S.
Clin Cancer Res. 2022 Jun 01; 28(11):2409-2424. PMID: 35344040. (* denotes Co-first authors)
Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
Alimova I, Wang D, Danis E, Pierce A, Donson A, Serkova N, Madhavan K, Lakshmanachetty S, Balakrishnan I, Foreman NK, Mitra S, Venkataraman S, Vibhakar R.
Int J Oncol. 2022 Mar; 60(3). PMID: 35179215; PMCID:PMC8878716.
New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S, Cruz-Cruz J, Hoffmeyer E, Cole AP, Mitra SS.
Cells. 2021 04 14; 10(4). PMID: 33919732; PMCID: PMC8070707.
Microglia in the Brain Tumor Microenvironment.
Cole AP, Hoffmeyer E, Chetty SL, Cruz-Cruz J, Hamrick F, Youssef O, Cheshier S, Mitra SS.
Adv Exp Med Biol. 2020; 1273:197-208. PMID: 33119883.
A complete list of the published work can be found here:
My Bibliography: https://www.ncbi.nlm.nih.gov/myncbi/1naFkuNwcmvks/bibliography/public/
Google Scholar: https://scholar.google.com/citations?user=geviFg4AAAAJ&hl=en